Iseda Norifumi, Itoh Shinji, Tomiyama Takahiro, Morinaga Akinari, Wang Huanlin, Shimagaki Tomonari, Kurihara Takeshi, Nagao Yoshihiro, Toshima Takeo, Harada Noboru, Iguchi Tomohiro, Yoshizumi Tomoharu, Mori Masaki
Dept. of Surgery and Science, Graduate School of Medical Sciences, Kyushu University.
Gan To Kagaku Ryoho. 2020 Sep;47(9):1303-1306.
Recently, immune checkpoint inhibitors(ICI)has been developed considerably. ICI has already been approved for malignant melanoma, lung cancer and renal cancer. We expected ICI to be taken for many cancers in the future. Therefore, the development of biomarker for them are needed. The recent large phase Ⅲ study IMbrave 150 evaluated atezolizumab plus bevacizumab vs sorafenib as the first treatment for patients with unresectable hepatocellular carcinoma(HCC). IMbrave 150 demonstrated statistically significant and clinically meaningful improvements in both OS and RFS for atezolizumab plus bevacizumab compared with sorafenib in HCC patients. A paradigm shift in the treatment of unresectable HCC is about to occur. In this article, we discussed the significance and biomarkers of tumor immunity in HCC microenvironment.
近年来，免疫检查点抑制剂（ICI）得到了长足发展。ICI已被批准用于恶性黑色素瘤、肺癌和肾癌。我们期望未来ICI能用于多种癌症。因此，需要为它们开发生物标志物。最近的大型Ⅲ期研究IMbrave 150评估了阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌（HCC）患者的一线治疗方案。IMbrave 150研究表明，与索拉非尼相比，阿替利珠单抗联合贝伐单抗治疗HCC患者的总生存期（OS）和无进展生存期（RFS）均有统计学意义且具有临床意义的改善。不可切除HCC的治疗即将发生范式转变。在本文中，我们讨论了HCC微环境中肿瘤免疫的意义和生物标志物。
